The wide-spread development, adoption and success of immunotherapies, such as CAR-T,continues to necessitate the development of new tools. To continue providing a safe and effective treatment option, immunotherapies will require robust assays for early development and preclinical studies. The identification and validation of cancer cell lines which express varying levels of tumor-associated antigens can aid in setting up standards for immune-oncology research. Our team has established a cell line engineering workflow for generating tumor-associated antigen panels in biologically-relevant cells. The endogenous protein expression is knocked out and the selected tumor antigen was then expressed at varying levels. These modified cell lines can be used as controls in validated assays or for the development of new potency assays for testing candidate immunotherapies.
Head of Portfolio Management
Ben currently leads a team of product and service managers within the Genome Engineering and Modulation franchise. His early experience with CRISPR-based genome editing inspired a passion for the technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing, from bench to bedside, revolutionary genome editing technologies. Ben has a PhD in computational biology from Washington University in St. Louis.